AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-21. Canceled

22.   (New) An albumin fusion protein comprising two or more tandemly oriented GLP-1 polypeptides, wherein said GLP-1 polypeptides are selected from wild-type GLP-1, GLP-1 fragments, or GLP-1 variants, wherein said GLP-1 fragments or GLP-1 variants have GLP-1 activity, fused to albumin comprising the amino acid sequence of SEQ ID NO:1038, an albumin fragment, or albumin variant thereof, wherein said albumin fragment or albumin variant increases the serum plasma half-life of the unfused GLP-1 polypeptides.

23.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from wild type GLP-1 sequences.

24.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 fragment sequences.

25.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 variant sequences.

-4-

26.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one' wild type GLP-1 sequence fused to at least one GLP-1 fragment sequence.

27.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one wild type GLP-1 sequence fused to at least one GLP-1 variant sequence.

28.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one GLP-1 fragment sequence fused to at least one GLP-1 variant sequence.

29.   (New) The albumin fusion protein of claim 22, wherein said GLP-1 fragments or GLP-1 variants are selected from:

a.   GLP-1(9-36);

b.   GLP-1(7-36);

c.   GLP-1(7-36(A8G)); and

d.   GLP-1(7-36(A8S)).

30.   (New) The albumin fusion protein of claim 29, wherein said GLP-1 fragments or GLP-1 variants are selected from two tandemly oriented GLP-1(7-36(A8G)).

31.   (New) The albumin fusion protein of claim 30, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the N-terminus to albumin.

32.   (New) The albumin fusion protein of claim 30, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the C-terminus to albumin.

33.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP -1 polypeptides are fused at the N-terminus to albumin.

34.   (New) The albumin fusion protein of claim 22, wherein said tandemly oriented GLP -1 polypeptides are fused at the C-terminus to albumin.

35.   (New) The albumin fusion protein of claim 22, produced from a host cell comprising a construct which expresses said albumin fusion protein, wherein said construct is selected from:

    a.   2900;

    b.   2964;

    c.   2803;

    d.   2804;

    e.   2945;

    f.   2982;

    g.   3070;

    h.   3027;

i.   3028;

j.   3045;

k.   3046;

l.   3069;

m.   3071;

n.   3072;

o.   3085;

p.   3086;

q.   3087;

r.   3309; and

s.   2904.

36.   (New) The albumin fusion protein of claim 22, which is non-glycosylated.

37.   (New) The albumin fusion protein of claim 22, which is expressed in yeast.

38.   (New) The albumin fusion protein of claim 37, wherein said yeast is a S. cerevisiae.

39.   (New) The albumin fusion protein of claim 37, wherein said yeast is glycosylation deficient.

40.   (New) The albumin fusion protein of claim 37, wherein said yeast is glycosylation and protease deficient.

41.   (New) The albumin fusion protein of claim 22, which is expressed by a mammalian cell.

42.   (New) The albumin fusion protein of claim 41, wherein said mammalian cell is a CHO cell.

43.   (New) The albumin fusion protein of claim 22, wherein the albumin fusion protein further comprises a secretion leader sequence.

44.   (New) A composition comprising the albumin fusion protein of claim 22 and a pharmaceutically acceptable carrier.

45.   (New) A method of treating a patient with diabetes, comprising administering an effective amount of the albumin fusion protein of any one of claims 22-43.